Therapeutic Reference Range for Clozapine Plasma Levels in Parkinson’s Disease or Dementia: A Systematic Review and Individual Participant Data Meta-analysis

Abstract

Introduction

Clozapine is a recommended treatment for psychotic symptoms in patients with Parkinson’s disease (PD) and/or dementia. However, the therapeutic reference range for clozapine in these patients has not been established hitherto.

Materials and Methods

The study was performed in three university hospitals in Germany and Switzerland, including clozapine-treated patients with PD and/or dementia. The primary outcome was tolerability based on reports of adverse drug reactions and/or changes in laboratory tests or electrocardiogram and/or clozapine discontinuation. We meta-analyzed demographic and pharmacokinetic parameters in patients tolerating clozapine well versus not. A meta-analytic summary receiver operating characteristic (SROC) to establish the clozapine upper level associated with poor tolerability was estimated.

Results

We analyzed a total of 99 patients suffering from PD (56.6%) and/or dementia (49.5%) with a mean age of 70.3±9.5 years and 41.4% females; poor tolerability was reported in 26 of 99 patients (26.3%). When comparing patients with and without poor tolerability, there were no differences in age, body mass index, sex, smoking, or clozapine dose, nor did we find statistically significant differences in clozapine levels (standardized mean difference 0.46, 95% confidence interval − 0.04 to 0.96, p=0.07), and heterogeneity was low (I²=0.0%). Clozapine blood levels above 193 ng/mL were associated with poor tolerability (SROC area-under-curve 0.6, sensitivity 39.7%, specificity 79.9%).

Conclusion

One of four patients with PD and/or dementia treated with clozapine did not tolerate clozapine well, which was associated with a trend toward elevated clozapine concentrations. Monitoring drug levels may help to improve tolerability in these patients.

Keywords

therapeutic drug monitoring - clozapine - Parkinson’s disease - dementia

Publikationsverlauf

Eingereicht: 30. August 2024

Angenommen nach Revision: 25. Januar 2025

Artikel online veröffentlicht:
17. April 2025

• References

• 1 Riedel O, Klotsche J, Spottke A. et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol 2010; 257: 1073-1082
• 2 MacK J, Rabins P, Anderson K. et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry 2012; 20: 123-132
• 3 Friedman A, Barcikowska M. Dementia in Parkinson’s disease. Dementia 1994; 5: 12-16
• 4 Stowe RL, Ives NJ, Clarke C. et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2008;
• 5 Morgante L, Colosimo C, Antonini A. et al. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 2012; 83: 76-82
• 6 Naasan G, Shdo SM, Rodriguez EM. et al. Psychosis in neurodegenerative disease: Differential patterns of hallucination and delusion symptoms. Brain 2021; 144: 999-1012
• 7 Cohen-Mansfield J, Cohen R, Golander H. et al. The impact of psychotic symptoms on the persons with dementia experiencing them. Am J Geriatr Psychiatry 2016; 24: 213-220
• 8 Mulsant BH. Challenges of the treatment of neuropsychiatric symptoms associated with dementia. Am J Geriatr Psychiatry 2014; 22: 317-320
• 9 Shotbolt P, David A, Samuel M. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord 2010; 3: 339-350
• 10 Höglinger G, Trenkwalder C, Bähr M. Diagnosis and treatment of Parkinson´s disease (guideline of the German Society for Neurology). Neurol Res Pract 2024; 6: 1-12
• 11 Factor SA, Brown D, Molho ES. et al. Clozapine: A 2-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994; 44: 544-546
• 12 Friedman JH, Koller WC, Lannon MC. et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 1997; 48: 1077-1081
• 13 Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757-763
• 14 Pollak P, Tison F, Rascol O. et al. Clozapine in drug induced psychosis in Parkinson’s disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689-695
• 15 Frieling H, Hillemacher T, Ziegenbein M. et al. Treating dopamimetic psychosis in Parkinson’s disease: Structured review and meta-analysis. Eur Neuropsychopharmacol 2007; 17: 165-171
• 16 Sivanandy P, Leey TC, Xiang TC. et al. Systematic review on Parkinson’s disease medications, emphasizing on three recently approved drugs to control Parkinson’s symptoms. Int J Environ Res Public Health 2021; 19
• 17 De Leon J, Arrojo-Romero M, Verdoux H. et al. Escaping the long shadow cast by agranulocytosis: Reflections on clozapine pharmacovigilance focused on the United Kingdom. J Clin Psychopharmacol 2023; 43: 239-245
• 18 Kuzo N, Haen E, Ho DM. et al. Clozapine once- versus multiple-daily dosing: A two-center cross-sectional study, systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2023; 273: 1567-1578
• 19 Tan MSA, Honarparvar F, Falconer JR. et al. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology (Berl) 2021; 238: 615-637
• 20 De Leon J, Schoretsanitis G, Smith RL. et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 2022; 55: 73-86
• 21 Gareri P, De Fazio P, Russo E. et al. The safety of clozapine in the elderly. Expert Opin Drug Saf 2008; 7: 525-538
• 22 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
• 23 de Filippis R, De las Cuevas C, Sanz EJ. et al. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database. Schizophr Res 2023;
• 24 Jiménez-Fernández S, Gurpegui M, Correll CU. et al. A systematic review of clozapine concentration–dose ratio from therapeutic drug monitoring studies in children and adolescents treated with clozapine for mental disorders. Ther Drug Monit 2024; 46: 170
• 25 Lutz UC, Sirfy A, Wiatr G. et al. Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol 2014; 70: 1471-1476
• 26 Zonana J, Zimmerman M, McCarty SS. et al. A case of abrupt-onset apathy, psychosis, and depression following deep brain stimulation in a patient with Parkinson’s disease. Psychosomatics 2011; 52: 463-467
• 27 Meltzer HY, Kennedy J, Dai J. et al Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson’s disease. Neuropsychopharmacology 1995; 12 2003; 12 39-45
• 28 Hely MA, Reid WGJ, Adena MA. et al. The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Movement Disorders 2008; 23: 837-844
• 29 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372
• 30 Hack N, Fayad SM, Monari EH. et al. An eight-year clinic experience with clozapine use in a Parkinson’s disease Clinic Setting. PLoS One 2014; 9: e91545
• 31 Herzog R, Álvarez-Pasquin MJ, Díaz C. et al. Are healthcare workers intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013; 13: 1-17
• 32 64th WMA General Assembly. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 2013; Im Internet https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ Stand: 25.04.2022
• 33 Bader W, Melchner D, Nonenmacher T. et al. Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and Electrochemical Detection. Pharmacopsychiatry 2005; 38: 4
• 34 Jukic MM, Smith RL, Haslemo T. et al. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: A retrospective, cohort study. Lancet Psychiatry 2019; 6: 418-426
• 35 Ansermot N, Brawand-Amey M, Kottelat A. et al. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. J Chromatogr A 2013; 1292: 160-172
• 36 Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70
• 37 Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R. 2015;
• 38 Steinhauser S, Schumacher M, Rücker G. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies. BMC Med Res Methodol 2016; 16
• 39 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 40 Higgins JPT, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 41 Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 42 Zhang Y, Hedo R, Rivera A. et al. Post hoc power analysis: Is it an informative and meaningful analysis?. Gen Psychiatr 2019; 32: e100069
• 43 Ucok A, Yağcıoğlu EA, Yıldız M. et al. Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. Psychiatry Res 2019; 275: 149-154
• 44 Schoretsanitis G, Anıl Yağcıoğlu AE, Ruan CJ. et al. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition. Schizophr Res 2024; 268
• 45 Hook A, Randall JL, Grubb CM. et al. Anti-cholinergic drug burden in patients with dementia increases after hospital admission: A multicentre cross-sectional study. BMC Geriatr 2022; 22